Next Article in Journal
Cardiovascular Safety of Two Bronchodilators’ Fixed-Dose Combination: Indacaterol and Glycopyrronium
Previous Article in Journal
Pulmonary Artery Stenosis Due to Embryonal Carcinoma with Primary Mediastinal Location
 
 
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Thixotropy of Nasal Medications—Its Role in Clinical Practice

by
Maciej Koźmiński
and
Maciej Kupczyk
*
Department of Internal Diseases, Asthma and Allergy, Medical University of Lodz, 90-153 Łódź, Poland
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2015, 83(2), 157-163; https://doi.org/10.5603/PiAP.2015.0025
Submission received: 13 January 2015 / Revised: 10 March 2015 / Accepted: 10 March 2015 / Published: 10 March 2015

Abstract

Optimal medication should be characterized by good bioavailability, rapid onset of action, a long period of therapeutic activity, with preserved high safety profile and the lowest possible risk of side effects. Therefore, in addition to traditional drug administration routes, such as oral or injection, novel methods for drug applications, for example in the form of a nasal application have been developed. Because of the anatomy of the nose, drugs administered intranasally can be rapidly absorbed and, depending on the nature of the active substance, may act locally on the mucosa or can have a significant systemic effect. Most nasal drugs are developed in the form of solution administered as aerosol. In some cases, these solutions are thixotropic. They are able to change their physical properties under agitation to facilitate supply of the drug and its adhesion to the mucosa. Intranasal corticosteroids represent the mainstay of treatment for any form of chronic allergic rhinitis (AR) and moderate to severe periodic AR, especially with impaired nasal obstruction and frequent occurrence of symptoms. The article discusses the rheological properties of intranasal corticosteroids, their role in therapy and efficacy in the everyday clinical practice.
Keywords: nasal spray; thixotropy; adhesion; nasal glucocorticosteroids nasal spray; thixotropy; adhesion; nasal glucocorticosteroids

Share and Cite

MDPI and ACS Style

Koźmiński, M.; Kupczyk, M. Thixotropy of Nasal Medications—Its Role in Clinical Practice. Adv. Respir. Med. 2015, 83, 157-163. https://doi.org/10.5603/PiAP.2015.0025

AMA Style

Koźmiński M, Kupczyk M. Thixotropy of Nasal Medications—Its Role in Clinical Practice. Advances in Respiratory Medicine. 2015; 83(2):157-163. https://doi.org/10.5603/PiAP.2015.0025

Chicago/Turabian Style

Koźmiński, Maciej, and Maciej Kupczyk. 2015. "Thixotropy of Nasal Medications—Its Role in Clinical Practice" Advances in Respiratory Medicine 83, no. 2: 157-163. https://doi.org/10.5603/PiAP.2015.0025

Article Metrics

Back to TopTop